7月2日 - ** 苏州瑞博生命科学（6938.HK）股价大涨10.7%，至51.9港元，创6月9日以来新高
** 这家总部位于中国的寡核苷酸开发商有望创下自4月1日以来最大的单日百分比涨幅
** 公司表示，在与Madrigal Pharmaceuticals Inc（MDGL.O）的siRNA合作中，已达成首个候选药物提名里程碑（(link)），旨在推进针对肝脏疾病的尖端RNA疗法，重点关注代谢功能障碍相关脂肪性肝炎（MASH）
** 本公司与Madrigal旨在利用本公司的肝脏靶向RiboGalSTAR平台开发具有前景的siRNA药物，为MASH患者提供更具靶向性和更有效的治疗方案——双方
** MASH是一种严重的肝病，可能进展为肝硬化、肝功能衰竭、肝癌，甚至需要进行肝移植，并导致过早死亡
** 自1月9日上市以来，苏州瑞博股价较发行价已下跌13.7%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.